
Primary Care On Demand: Diabetes Vol. 3
![]() Hurry! Offer expires September 15, 2023 at 11:59 pm ET!
|
|
Course Content
Session | Title | Faculty |
Session 1 (47 minutes) | Type 2 Diabetes Guidelines | S. Inzucchi, MD |
Session 2 (44 minutes) | Treatment of Type 2 Diabetes: A Sound Approach Based on Its Pathophysiology | J. Buse, MD, PhD |
Session 3 (44 minutes) | Practical Aspects of Using Newer Diabetes Medications: SGLT2 Inhibitors and GLP-1 Receptor Agonists | S. Inzucchi, MD |
Session 4 (49 minutes) | Type 2 Diabetes: What Have the Latest Trials on Older Drugs Told Us? | J. Buse, MD, PhD |
Session 5 (63 minutes) | Cases in Diabetes | J. Buse, MD, PhD & S. Inzucchi, MD |
Session 6 (62 minutes) | Contrasting the GLP-1 and Dual Incretin Receptor Agonists with SGLT2 Inhibitors in the Early Treatment of Diabetes | M. McDonnell, MD |
Session 7 (46 minutes) | Novel Medications for Resistant Hypertension: What the Future Holds | G. Bakris, MD |
Session 8 (47 minutes) | Selecting Therapies in the Older Outpatient with Diabetes: A Cardiometabolic Approach | M. McDonnell, MD |
Session 9 (58 minutes) | “Pillars of Therapy”: The 21st Century Approach to Halting Nephropathy from Diabetes | G. Bakris, MD |
Session 10 (81 minutes) | Cases in Diabetes, Kidney, and Cardio-Renal Disease | M. McDonnell, MD & G. Bakris, MD |
Program Overview
Primary Care On Demand: Diabetes Volume 3 will educate and promote improved patient outcomes for type 2 diabetes related issues commonly encountered in internal medicine and family medicine practice. This CME course will highlight the latest science related to diabetes, presented in a practical and patient-focused manner relevant to the primary care setting. It reviews the clinical presentation, diagnostic tests, and management strategies related to diabetes.
Presented by Continuing Education Company (CEC) for over 30 years, our Primary Care CME Conference Series is designed to update primary care clinicians in rapidly changing therapeutic areas. This CME activity, Primary Care On Demand: Diabetes is comprised of recorded video lectures taken from CEC’s recent live specialty conferences on the topics of Diabetes, Obesity, Metabolic Disease, Hypertension, and Dyslipidemia.
Learning Objectives:
As a result of this educational activity, participants should be better able to:
- Formulate an efficient and effective assessment and monitoring plan of a patient’s condition as it relates to diabetes.
- Utilize current guidelines in the diagnosis and management of diabetes.
- Develop individualized interventions and treatment strategies for patients presenting with diabetes that will lead to the reduction of modifiable risk factors and improved long term outcomes.
Post-Test and Evaluation:
After completing the CME activity, you must successfully complete a post-test and fill out a program evaluation form. You will then be able to view and print your CME certificate.
Faculty
George Bakris, MD, MA, FASH, FASN, FAHA
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
The University of Chicago Medicine
Chicago, IL
John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Senior Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, NC
Silvio E. Inzucchi, MD
Professor of Medicine, Endocrinology
Clinical Director, Section of Endocrinology
Director, Yale Diabetes Center
Director, Endocrinology & Metabolism Fellowship
Director, Yale Affiliated Hospitals
Yale School of Medicine
New Haven, CT
Marie E. McDonnell, MD
Chief, Diabetes Section
Division of Endocrinology, Diabetes and Hypertension
Associate Professor of Medicine, Harvard Medical School
Brigham and Women's Hospital
Arlington, MA
Accreditation
AMA PRA Category 1 Credits™: Continuing Education Company, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Continuing Education Company, Inc. designates this enduring material for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST complete the activity and the evaluation form. For ABIM MOC points, your information will be shared with the ABIM through the ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 9 hours of Category 1 credit for completing this activity.
AANPCB: The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Nurse Practitioners may receive a maximum of 9 hours of participation for completing this activity, 5.5 of which can be used towards Pharmacology, for completing this activity.
Release Date: 6/2/2023
Expiration Date: 6/2/2026 (Date after which this enduring material is no longer certified for credit.)
Medium: Internet/Enduring Material, Video/Audio
Faculty/Planning Committee Disclosures
Review and Planning Committee Disclosures:
The following individuals have indicated that he/she (nor spouse/partner) has no relevant financial relationships with a commercial interest that may impact upon this CME activity:
- Raymond E. Major, MD – Reviewer
- Su Barnwell – Planner (Continuing Education Company)
- Walter Ejnes, CHCP – Reviewer & Planning Committee (Continuing Education Company)
- Lizzie Masters – Reviewer (Continuing Education Company)
- Beth Ryan Townsend, CHCP – Reviewer (Continuing Education Company)
Faculty Disclosures:
The following individuals have indicated that he/she (nor spouse/partner) have no relevant financial relationships with a commercial interest that may impact upon this CME activity:
Faculty | Disclosure |
George Bakris, MD | Advisory Board, Consultant/ Executive Committee of Clinical Trials: Ionis Consultant/ Executive Committee of Clinical Trials: Alnylam; Astra Zeneca; Bayer; InREGEN; Janssen; KBP Biosciences; Novo Nordisk Editor: AM J Nephrology Employment: University of Chicago Medicine, supported by T32 NIH grant DK07011 |
John B. Buse, MD, PhD | Consultant: Alkahest; Altimmune; Anji; Bayer; Biomea Fusion; Boehringer-Ingelheim; CeQur; Cirius Therapeutics, Inc.; Dasman Diabetes Center (Kuwait); Eli Lilly; Fortress Biotech; GentiBio; Glycadia; Glyscend; Janssen; MannKind; Mediflix; Medimmune; MedScape; Mellitus Health; Moderna; Pendulum Therapeutics; Praetego; Stability Health; Valo; Zealand Pharma Grant Recipient: National Institute of Health (UL1TR002489, U01DK098246, UC4DK108612, U54DK118612, P30DK124723, R33HL142680, R44DK096803, R01DK119913, R01DK112939, R01DK125831, R01DK127365); PCORI (D1-2018C1-10853) Research Grant: Sanofi Research Grant, fees for consultation to UNC: Dexcom; NovaTarg; Novo Nordisk; Tolerion; vTv Therapeutics Stockholder, In lieu of payment receiving stock options: Glyscend; Mellitus Health; Pendulum Therapeutics; Phase Bio; Praetego; Stability Health |
Silvio E. Inzucchi, MD | Advisory Board: AstraZeneca; Boehringer Ingelheim; Novo Nordisk; vTv Therapeutics Consultant: Abbott; AstraZeneca; Esperion; Lexicon; Merck/Pfizer Clinical Trial Executive Committee: AstraZeneca Clinical Trial Publications Committee: Boehringer Ingelheim Clinical Trial Steering Committee: Novo Nordisk Lectures: AstraZeneca; Boehringer Ingelheim |
Marie McDonnell, MD | Nothing to disclose. |
Unlabeled Use Declaration:
During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.
Statement of Disclosure and Independence:
It is the policy of Continuing Education Company (CEC) to ensure all of its accredited educational activities are designed, implemented, and evaluated in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Criteria and Policies. In accordance with ACCME requirements, CEC has Relevant Financial Relationship Disclosure Policies that are designed to ensure that accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.
All individuals who are in position to influence and/or control content of a CEC accredited Continuing Medical Education (CME) activity must disclose any relevant financial interest or other relationships they have with an ineligible company, which is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Relevant financial interest or other relationship includes such things as grants or research support, employee, consultant, major stockholder, member of speakers’ bureau, etc.) The intent of this disclosure is to provide activity participants with information to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusions. All relevant financial relationships have been identified, mitigated, and are listed above.
The opinions, ideas, recommendations, and perspectives expressed in the syllabus and accompanying presentations at this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Continuing Education Company, advisory boards or consultants.
Computer Requirements
Flash Player 10 or later, and one of the following browsers:
- Windows: Internet Explorer 6 and later, Microsoft Edge (latest version), Firefox 1.x and later, Google Chrome (latest version), Opera 9.5 and later
- Mac: Safari 3 and later, Firefox 1.x and later, Google Chrome (latest version)
- Linux: Firefox 1.x and later
HTML5 via one of the following browsers:
- Windows: Google Chrome (latest version)
- Mac: Safari 6.0.5 or later, Google Chrome (latest version)
- Mobile: Safari in Apple iOS 6 or later

30 Day Money Back Guarantee
CEC stands behind our product. If you are not satisfied with your online course for any reason, send a written cancellation request and reason to registration@cmemeeting.org within 30 days of the purchase date for a full refund. (Cancellations on CME365™ Collection Series will incur a 5% processing fee.) Please note you may watch any of the content but once you claim credit for any online course, no refund can be granted.